The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
Abstract
CONTEXT: Recently published results suggest that effective vaccines against cervical cancer-associated human papillomavirus (HPV) may become available within the next decade. OBJECTIVE: To examine the potential health and economic effects of an HPV vaccine in a setting of existing screening. DESIGN, SETTING, AND POPULATION: A Markov model was used to estimate the lifetime (age 12-85 years) costs and life expectancy of a hypothetical cohort of women screened for cervical cancer in the United States. Three strategies were compared: (1) vaccination only; (2) conventional cytological screening only; and (3) vaccination followed by screening. Two of the strategies incorporated a vaccine targeted against a defined proportion of high-risk (oncogenic) HPV types. Screening intervals of 1, 2, 3, and 5 years and starting ages for screening of 18, 22, 24, 26, and 30 years were chosen for 2 of the strategies (conventional cytological screening only and vaccination followed by screening). MAIN OUTCOME MEASURES: Incremental cost per life-year gained. RESULTS: Vaccination only or adding vaccination to screening conducted every 3 and 5 years was not cost-effective. However, at more frequent screening intervals, strategies combining vaccination and screening were preferred. Vaccination plus biennial screening delayed until age 24 years had the most attractive cost-effectiveness ratio (44 889 dollars) compared with screening only beginning at age 18 years and conducted every 3 years. However, the strategy of vaccination with annual screening beginning at age 18 years had the largest overall reduction in cancer incidence and mortality at a cost of 236 250 dollars per life-year gained compared with vaccination and annual screening beginning at age 22 years. The cost-effectiveness of vaccination plus delayed screening was highly sensitive to age of vaccination, duration of vaccine efficacy, and cost of vaccination. CONCLUSIONS: Vaccination for HPV in combination with screening can be a cost-effective health intervention, but it depends on maintaining effectiveness during the ages of peak oncogenic HPV incidence. Identifying the optimal age for vaccination should be a top research priority.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., Shan, K. V., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.11.796 · Cited by 3,370
The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>
Solomon, D. (2002) · JAMA · doi:10.1001/jama.287.16.2114 · Cited by 3,104
Natural History of Cervicovaginal Papillomavirus Infection in Young Women
Ho, G. Y. F., Bierman, R., Beardsley, L., Chang, C. J., & Burk, R. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380703 · Cited by 2,329
NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN
Loria, G. R., Ierman, R. O. B., Eardsley, L. E. B., & Hang, H. J. C. (1998) · Cited by 1,890
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., & Matchar, D. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00009 · Cited by 1,089
Self-citationSolomon, D., Schiffman, M., & Tarone, R. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.293 · Cited by 975
Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D., & Kiviat, N. B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271804 · Cited by 943
American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer
Saslow, D., Runowicz, C. D., Solomon, D., Moscicki, A.-B., Smith, R. A., Eyre, H. J., & Cohen, C. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.6.342 · Cited by 927
Eddy, D. M. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-3-214 · Cited by 837
The 2001 Bethesda System: Terminology for Reporting Results of Cervical Cytology
Solomon, D., Davey, D., Kurman, R., Moriarty, A., O’Connor, D., Prey, M., Raab, S., Sherman, M., Wilbur, D., & Wright, T. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200208000-00015 · Cited by 822
Myers, E. R., McCrory, D. C., Nanda, K., Bastian, L., & Matchar, D. B. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010166 · Cited by 470
Kulasingam, S. L., Hughes, J. P., Kiviat, N. B., Mao, C., Weiss, N. S., Kuypers, J. M., & Koutsky, L. A. (2002) · JAMA · doi:10.1001/jama.288.14.1749 · Cited by 452
Self-citationVaccines for the 21st Century: A Tool for Decisionmaking
Stratton, K. R., Durch, J. S., & Lawrence, R. S. (2013) · Cited by 444
(ALTS) Group, T. A. S. C. O. U. S. /.-G. S. I. L. T. S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.397 · Cited by 438
Gustafsson, L., Pontén, J., Zack, M., & Adami, H.-O. (1997) · Cancer Causes & Control · doi:10.1023/a:1018435522475 · Cited by 398
Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment
Winkelmayer, W. C., Weinstein, M. C., Mittleman, M. A., Glynn, R. J., & Pliskin, J. S. (2002) · Medical Decision Making · doi:10.1177/027298902236927 · Cited by 341
Goldie, S. J., Kuhn, L., Denny, L., Pollack, A., & Wright, T. C. (2001) · JAMA · doi:10.1001/jama.285.24.3107 · Cited by 335
Human papillomavirus testing in primary cervical screening
Cuzick, J., Szarewski, A., Terry, G., Hanby, A., Maddox, P., Anderson, M., Steele, S. J., Guillebaud, J., & Kocjean, C. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91086-7 · Cited by 328
Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer
Mandelblatt, J. S. (2002) · JAMA · doi:10.1001/jama.287.18.2372 · Cited by 308
Jacobs, M. V., Walboomers, J. M. M., Snijders, P. J. F., Voorhorst, F. J., Verheijen, R. H. M., Fransen-Daalmeijer, N., & Meijer, C. J. L. M. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000715)87:2<221::aid-ijc11>3.0.co;2-2 · Cited by 277
Kim, J. J. (2002) · JAMA · doi:10.1001/jama.287.18.2382 · Cited by 269
Liaw, K.-L., Glass, A. G., Manos, M. M., Greer, C. E., Scott, D. R., Sherman, M., Burk, R. D., Kurman, R. J., Wacholder, S., Rush, B. B., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.954 · Cited by 242
Human papillomavirus testing for primary screening of cervical cancer precursors.
Ratnam, S., Franco, E. L., & Ferenczy, A. S. (2000) · PubMed · Cited by 240
The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine
Hughes, J. P., Garnett, G. P., & Koutsky, L. (2002) · Epidemiology · doi:10.1097/00001648-200211000-00006 · Cited by 230
Concurrent and Sequential Acquisition of Different Genital Human Papillomavirus Types
Thomas, K. K., Hughes, J. P., Kuypers, J. M., Kiviat, N. B., Lee, S., Adam, D. E., & Koutsky, L. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315805 · Cited by 197
Coste, J., Cochand-Priollet, B., de Cremoux, P., Galès, C. L., Isabelle, C., Vincent, M., Labbé, S., Vacher-Lavenu, M.-C., & Vielh, P. (2003) · BMJ · doi:10.1136/bmj.326.7392.733 · Cited by 181
Focusing Technology Assessment Using Medical Decision Theory
Phelps, C. E., & Mushlin, A. I. (1988) · Medical Decision Making · doi:10.1177/0272989x8800800409 · Cited by 168
Cost Effectiveness of Cervical Cancer Screening for the Elderly
Fahs, M. C., Mandelblatt, J. S., Schechter, C. B., & Muller, C. F. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-520 · Cited by 141
Human papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Klee, M., Thranov, I., & Machin, D. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5644 · Cited by 130
Nanda, K., McCrory, D., Er, M., Bastian, L., Hasselblad, V., Hickey, J., & Matchar, D. B. (2001) · Journal of Lower Genital Tract Disease · doi:10.1046/j.1526-0976.2001.51012-12.x · Cited by 129
Cost-effectiveness of 3 Methods to Enhance the Sensitivity of Papanicolaou Testing
Brown, A. D., & Garber, A. M. (1999) · JAMA · doi:10.1001/jama.281.4.347 · Cited by 124
Sexual behavior of American adolescents: Results from a U.S. national survey
Leigh, B. C., Morrison, D. M., Trocki, K. F., & Temple, M. T. (1994) · Journal of Adolescent Health · doi:10.1016/1054-139x(94)90538-x · Cited by 115
Myers, E. R., McCrory, D. C., Subramanian, S., McCall, N., Nanda, K., Datta, S., & Matchar, D. B. (2000) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(00)00979-0 · Cited by 100
Does Liquid-Based Technology Really Improve Detection of Cervical Neoplasia?
Obwegeser, J. H., & Brack, S. (2001) · Acta Cytologica · doi:10.1159/000328292 · Cited by 95
HPV Testing is Not Useful for LSIL Triage???But Stay Tuned
Stoler, M. H. (2001) · Advances in Anatomic Pathology · doi:10.1097/00125480-200105000-00004 · Cited by 92
Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J. A., Beckmann, A. M., DeBOUEN, T. A., Galloway, D. A., Vernon, D., & Kiviat, N. B. (1993) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199303000-00018 · Cited by 90
Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection
Anderson, R. M., Swinton, J., & Garnett, G. P. (1995) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1995.0129 · Cited by 51
Maxwell, G. L., Carlson, J. W., Ochoa, M., Krivak, T., Rose, G. S., & Myers, E. R. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02195-6 · Cited by 51
Evaluating cervical cancer screening programmes for developing countries
Sherlaw‐Johnson, C., Gallivan, S., & Jenkins, D. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970717)72:2<210::aid-ijc2>3.0.co;2-u · Cited by 48
Human papillomavirus testing in primary cervical screening
Sun, X.-W., Koulos, J. P., Felix, J., Ferenczy, A. S., Richart, R., Park, T., & Wright, T. C. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91466-8 · Cited by 37
Woolf, S. H. (1990) · Frontiers of primary care · doi:10.1007/978-1-4612-3280-3_32 · Cited by 26
Cited by
Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007) · PsycEXTRA Dataset · doi:10.1037/e601292007-001 · Cited by 1,882
Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J., Garcia, F. A. R., Moriarty, A. T., Waxman, A. G., Wilbur, D. C., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21139 · Cited by 1,390
Self-citationThe epidemiology of human papillomavirus infections
Baseman, J. G., & Koutsky, L. A. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.12.008 · Cited by 955
Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J. M., Garcia, F. A. R., Moriarty, A. T., Waxman, A. G., Wilbur, D. C., et al. (2012) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e31824ca9d5 · Cited by 915
Self-citationSaslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J., Garcia, F. A. R., Moriarty, A. T., Waxman, A. G., Wilbur, D. C., et al. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcptgd94evrsjcg · Cited by 791
Self-citation
Metadata
- Authors
- Kulasingam, S. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-08-13
- Volume
- 290
- Issue
- 6
- Pages
- 781
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1982987943
- Cited by
- 337
- References
- 45
- FWCI
- 17.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.